Safety and Efficacy of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia (HoFH): Results from the AEGR-733-301 Long-Term Extension Study

Aim: Lomitapide is an approved lipid-lowering agent indicated as adjunct to low-fat diet and standard lipid-lowering therapies (LLTs) including lipoprotein apheresis for the treatment of homozygous familial hypercholesterolemia (HoFH). Clinical data from Phase 3 studies have demonstrated the prolong...

Descripción completa

Detalles Bibliográficos
Autores principales: Nohara, Atsushi, Otsubo, Yoshihiko, Yanagi, Koji, Yoshida, Masayuki, Ikewaki, Katsunori, Harada-Shiba, Mariko, Jurecka, Agnieszka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japan Atherosclerosis Society 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6456458/
https://www.ncbi.nlm.nih.gov/pubmed/30259883
http://dx.doi.org/10.5551/jat.45708

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6456458/
https://www.ncbi.nlm.nih.gov/pubmed/30259883
http://dx.doi.org/10.5551/jat.45708

Ejemplares similares